Teva Pharmaceutical Industries Ltd.'s investors have run out of patience as the company's generic drug business continues to struggle, even after the completion of an expensive acquisition last year, and as financial targets were missed again in the second quarter – all without a permanent CEO at the helm.
Teva SOS: Troubled Drug Maker Seeks Audacious Captain To Take The Wheel
Teva investors have moved beyond restless to the point of jumping ship as the company's generic drug business continues to underperform, with little guidance on plans for a turnaround.